Abstract
618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have